Skip to main content
. 2015 Mar 18;10(3):e0120157. doi: 10.1371/journal.pone.0120157

Fig 2. Eicosanoid metabolite concentrations (expressed in ng/mg lung tissue weight) in the lungs.

Fig 2

There is an increase in 6-ketoPGF1α (The stable metabolite of prostacyclin), and of PGE2 in the SuHx lung tissues. There was a trend for an increase of the LTC4 and LTD4 levels. Chronic treatment of SuHx rats with the COX-2 inhibitor SC-58125 did not prevent the increase in lung tissue concentration of 6-ketoPGF1α or PGE2 (A, C). The COX-2inhibitor trended to affect the lung tissue increase of the LTC4 and LTD4 (E, F). * P<0.05 vs. control, #P<0.05 vs. SuHx. (n = 4).